Introduction
============

Head and neck squamous cell carcinoma (HNSC) is one of the most common types of cancer worldwide ([@b1-ol-0-0-10213]). According to a recent study, 108,700 new cases were identified and 56,200 mortalities occurred as a result of HNSC in China in 2015 ([@b2-ol-0-0-10213]). The reasons behind HNSC carcinogenesis include smoking and human papilloma virus (HPV) infection ([@b3-ol-0-0-10213]). The 5-year survival rate of HNSC is estimated to be \~50% ([@b4-ol-0-0-10213]); although novel treatment methods have been utilized, the survival rate has not improved significantly over recent decades ([@b5-ol-0-0-10213]). Therefore, a prognostic model was urgently required.

Non-coding RNAs, particularly long non-coding RNAs (lncRNAs), have been the subjects of considerable attention in recent years, although the abundance of these RNAs is much lower than that of mRNAs ([@b6-ol-0-0-10213]). lncRNAs serve crucial roles in various cellular processes in HNSC, including carcinogenesis and progression ([@b6-ol-0-0-10213]--[@b14-ol-0-0-10213]). Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was identified as an oncogene, and the high expression of MALAT1 is associated with metastasis and poor survival across different cancer types ([@b15-ol-0-0-10213]--[@b17-ol-0-0-10213]). Suppression of HOX transcript antisense RNA expression was reported to induce apoptosis and to inhibit proliferation of HNSC cells ([@b18-ol-0-0-10213]). In addition to their use as prognostic markers, certain lncRNAs, including growth arrest specific 5, were reported to be participate in treatment response ([@b19-ol-0-0-10213]). Chemotherapy drugs, including cisplatin and paclitaxel, have been demonstrated to exert effects on lncRNAs ([@b20-ol-0-0-10213]), to a certain extent.

In line with this, lncRNAs and mRNAs significantly associated with survival were identified using Cox univariate regression based on two independent datasets. To facilitate the utilization and to reduce the size of the panel, random forest variable hunting was implemented and 17 lncRNA-mRNAs were used to develop the model, which estimated the survival with risk scores. The risk score was significantly associated with survival in all the training and test datasets involved. Association analyses revealed that the risk score is a prognostic factor that is independent of other clinical observations.

Materials and methods
=====================

### Raw data pre-processing

The Cancer Genome Atlas (TCGA) expression data evaluated using RNA-seq was downloaded from the TCGA website (<http://cancergenome.nih.gov/>), the upper quantile fragments per kilobase per million (FPKM) method ([@b21-ol-0-0-10213]) was used to normalize primary HNSC samples. The normal, recurrent and metastatic samples were removed and genes expressed in \<80% samples were excluded for further analysis. Half of the minimum FPKM value (except for zero) was used in order to avoid zero values for each gene. Subsequently, the expression data were log~2~-transformed. The pre-processed data was then z-transformed for further analysis. The raw microarrays data were downloaded from the Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo>) and the ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) websites ([@b21-ol-0-0-10213]--[@b23-ol-0-0-10213]). Following background correction and normalization, the expression values were calculated. If several probes represented the same gene, the mean value was used as the expression value. Z-scores of each sample in each dataset were also evaluated. The probes were matched to lncRNAs, as described in a previous study ([@b24-ol-0-0-10213]).

### Prediction of gene selection and Cox multivariate regression model

Cox univariate regression was performed on the Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma (TCGA-HNSC) (n=407) and GSE41613 (n=97) datasets ([@b24-ol-0-0-10213]), and the lncRNAs/mRNAs significantly associated with overall survival (OS) (P\<0.01) in the two datasets were identified as candidate genes, with 87 genes being identified. To narrow down the panel and optimize the results, random forest variable hunting was performed to identify biomarker combinations for survival prediction with 100 replications and 100 iterations, using z-score-transformed expression values and OS information. The selected 17 lncRNAs and mRNAs were used to develop the Cox multivariate regression model, with the 'coxph' function in the R package 'survival' ([@b25-ol-0-0-10213]). In the validation datasets, coefficients were locked and the risk score for each sample was calculated. The risk score was calculated using the following formula; where β indicates the coefficients evaluated with gene expression and x~i~ refers to the relative gene expression level.
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The risk score of each sample was calculated in each dataset, and the median risk score value of each dataset was used to divide the high-risk and low-risk group.

### Statistical analysis

All statistical analyses involved in the present study were implemented on R (<https://www.r-project.org/>; v3.0.1) platform and R packages. Normalization of Affymetrix raw data was performed using the R package 'affy' ([@b26-ol-0-0-10213]) using function 'rma'. The survival analysis and Cox proportional hazards model was performed using the R package 'survival' and the random forest for variable hunting performed using the package 'randomForestSRC' ([@b27-ol-0-0-10213],[@b28-ol-0-0-10213]). The receiver operating characteristic curves were drawn using R package 'pROC' ([@b25-ol-0-0-10213]), and the nomogram was drawn using R package 'rms' ([@b29-ol-0-0-10213]).

Results
=======

### Identification of 87 survival-associated mRNAs and lncRNAs

Over-fit often occurs in model development. To avoid this, Cox univariate regression was implement in two independent datasets, TCGA-HNSC (n=407) and GSE41613 (n=97). lncRNAs and mRNAs detected in the two platforms (next-generation sequencing assembly by TCGA and affymetrix HG U133 plus 2) were retained for further analysis. The mRNAs and lncRNAs that were significantly associated with overall survival in the two datasets (Cox univariate regression; P\<0.01) were retained for further analysis. In total, 87 genes, including 10 lncRNAs and 77 mRNAs, were identified. To reduce redundancy, a random forest variable hunting algorithm was implemented to optimize the panel of lncRNAs and mRNAs. Finally, 17 genes (14 mRNAs and 3 lncRNAs) were identified ([Fig. 1A](#f1-ol-0-0-10213){ref-type="fig"}). The coefficients of 8 genes were negative and those of 9 other genes were positive ([Fig. 1B](#f1-ol-0-0-10213){ref-type="fig"}). The Cox univariate regression and multivariate regression parameters are presented in [Table I](#tI-ol-0-0-10213){ref-type="table"}.

### Risk score in the training dataset

Cox multivariable regression was used to develop the risk score model based on the z-score that transformed the 17 gene expression in the largest cohort, TCGA-HNSC dataset. The risk scores of samples in each dataset were calculated using the following formula: Risk score=(−0.0250\*ENSG00000261408) + (−0.2286\*zinc finger protein 266) + (0.2334\*proteasome 26S subunit, ATPase 1) + (0.5152\*ribosomal protein L26 like 1) + (0.1220\*WD repeat domain 54) + (0.0203\*ENSG00000265206) + (0.4167\*interleukin 1 receptor accessory protein) + (−0.0133\*C-type lectin domain containing 10A) + (0.3976\*spermine synthase) + (−0.2395\*sushi repeat containing protein, X-linked) + (0.2100\*protein tyrosine phosphatase, non-receptor type 9) + (−0.2305\*RAB24, member RAS oncogene family) + (−0.3801\*leucine rich repeat containing 38) + (1.5993\*ENSG00000261777) + (0.5527\*mitochondrial methionyl-tRNA formyltransferase) + (−2.2410\*cornifelin) + (−0.0681\*class II major histocompatibility complex transactivator). The risk score for each patient was calculated, and the samples were divided into high-risk and low-risk groups using the median risk scores of the TCGA-HNSC samples as cut-off values. The OS times of the high-risk group were significantly (P\<0.05) shorter than that of the low-risk group ([Fig. 2A](#f2-ol-0-0-10213){ref-type="fig"}). The recurrence-free survival rate was also evaluated in TCGA-HNSC dataset, with the results demonstrating that the high-risk group exhibited significantly shorter recurrence-free survival (RFS) times ([Fig. 2B](#f2-ol-0-0-10213){ref-type="fig"}). The high-risk group samples tend to have lower survival rates, high expression of oncogenes and low expression of tumor suppressor genes ([Fig. 2C](#f2-ol-0-0-10213){ref-type="fig"}). In order to test the robustness of the risk score, P-values were calculated by retrieving 80% of samples from the dataset (K-fold), and this process was repeated 10,000 times. In 92.59% of cases, the difference in survival rate between the risk-high and risk-low groups was statistically significant, as depicted in [Fig. 2D](#f2-ol-0-0-10213){ref-type="fig"}.

### Risk-score performance validation

The high performance of the risk score may result from over-fit; thus, the robustness of the risk score was further validated in other independent datasets, GSE41613 (n=97), GSE10300 (n=81) and E-TABM-302 (n=81). Following the locking of coefficients in each dataset, the risk scores were calculated and the high/low-risk groups were divided according to the median risk score in each dataset. The overall survival (OS) and recurrence-free survival (RFS) of the high-risk group were significantly lower than those of the low-risk group ([Fig. 3A-C](#f3-ol-0-0-10213){ref-type="fig"}, top). The expression patterns of these 17 genes in these datasets was similar to those of the training dataset ([Fig. 3A-C](#f3-ol-0-0-10213){ref-type="fig"}). Together, these results indicated that the risk-score staging model was robust across datasets and platforms (RNA-seq and microarray).

To test the performance of random forest variable hunting, which has previously been used for biomarker combination screening ([@b24-ol-0-0-10213],[@b26-ol-0-0-10213]), 20 randomly-selected 17-gene panels were generated, and the risk score model was developed using these genes. However, the majority of combinations were not statistically significantly different in the four datasets (17/20; [Table II](#tII-ol-0-0-10213){ref-type="table"}), indicating that random forest variable hunting is a powerful tool for candidate gene selection.

### Risk score and clinicopathological observations

Association analyses between risk score and other clinical observations were performed in the largest dataset, TCGA-HNSC. The results revealed that the risk score was able to predict prognosis independently of sex, differentiation grade and primary tumor size ([Fig. 4A](#f4-ol-0-0-10213){ref-type="fig"}), indicating that the risk score served as an independent prognostic indicator. To facilitate the utilization of the risk score and to evaluate its importance among clinical observations, a nomogram ([Fig. 4B](#f4-ol-0-0-10213){ref-type="fig"}) for the 3-year OS rate was plotted, and it was demonstrated that the risk score was the most important predictor of the 3-year OS rate (range, 0--100). Taken together, the aforementioned results indicated that the 17 lncRNA-mRNA-based risk score is an independent clinical indicator and that it is more efficient in predicting survival than other clinical observations.

### Risk score and radiation therapy

In the present study, patients were artificially divided into radiation-receiving and non-radiation-receiving groups. These groups were further divided into high-risk and low-risk groups based on their corresponding median risk score values. The high-risk group exhibited a significantly poorer survival rate in the radiation-receiving ([Fig. 5A](#f5-ol-0-0-10213){ref-type="fig"}) and non-radiation-receiving groups ([Fig. 5B](#f5-ol-0-0-10213){ref-type="fig"}), indicating that the risk score was a prognostic indicator independent to radiation therapy.

Discussion
==========

In the present study, using the expression of lncRNAs and mRNAs and random forest variable hunting, a risk-score model was developed and was further validated in another three independent datasets. Furthermore, the risk score is independent of other clinicopathological observations and performs better at survival-prediction than other clinical characteristics.

The clinical outcome of HNSC carcinoma is affected by the heterogeneity of cancer, treatment method and surgery, the latter of which is controllable, while heterogeneity. Therefore, it is important to elucidate the molecular mechanisms underlying the heterogeneity of HNSC carcinoma ([@b27-ol-0-0-10213]). Clinically, HNSC may result from multiple causes, including smoking, HPV infection and diet, which makes the survival-prediction of HNSC difficult to determine using clinicopathological observations. Another indication of this heterogeneity is that no single gene was associated with survival in all datasets used in the present study. On the other hand, a multigene-based model is more robust in predicting prognosis, according to previous studies ([@b24-ol-0-0-10213],[@b28-ol-0-0-10213]--[@b31-ol-0-0-10213]). lncRNAs and mRNAs are notable regulators of carcinogenesis and cancer development ([@b32-ol-0-0-10213],[@b33-ol-0-0-10213]).

However, there are limitations to the present study. To begin with, owing to the retrospective nature of the study, important clinical indictors, including the resection margin of surgery and the drugs used during the therapeutic period, were not available. Secondly, although the risk score is an independent prognostic factor, pooled data were required to facilitate its utilization.

In summary, the 17 lncRNA-mRNA-based model is robust across different platforms and is a better survival predictor than other factors.
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###### 

Cox univariate and multivariate regression of genes involved.

                    Univariate Cox regression   Multivariate Cox regression                                  
  ----------------- --------------------------- ----------------------------- --------- ------ ------------- ---------
  WDR54             2.30                        1.30--4.10                    0.004     0.68   0.32--1.47    0.330
  RPL26L1           3.90                        1.40--10.00                   0.007     4.95   1.38--17.73   0.014
  PSMC1             5.20                        2.00--14.00                   0.001     1.74   0.60--5.07    0.311
  SRPX              1.50                        1.10--2.10                    0.006     0.99   0.68--1.44    0.945
  SMS               2.80                        1.40--5.50                    0.003     1.49   0.60--3.66    0.387
  MTFMT             4.50                        1.50--13.00                   0.007     1.26   0.32--4.91    0.736
  CNFN              0.77                        0.64--0.93                    0.007     0.80   0.62--1.02    0.070
  CLEC10A           0.59                        0.44--0.80                    0.001     0.79   0.49--1.25    0.314
  LRRC38            1.30                        1.10--1.60                    0.007     1.13   0.92--1.39    0.252
  RAB24             0.42                        0.23--0.76                    0.005     1.02   0.41--2.52    0.965
  PTPN9             4.10                        1.40--12.00                   0.008     1.52   0.36--6.38    0.570
  ZNF266            0.11                        0.045--0.26                   \<0.001   0.11   0.04--0.29    \<0.001
  CIITA             0.60                        0.43--0.83                    0.002     0.98   0.59--1.62    0.924
  IL1RAP            2.00                        1.20--3.40                    0.009     1.23   0.70--2.18    0.468
  ENSG00000261408   0.53                        0.34--0.84                    0.007     0.93   0.51--1.71    0.826
  ENSG00000261777   1.90                        1.20--3.10                    0.009     1.67   0.95--2.95    0.074
  ENSG00000265206   0.55                        0.42--0.73                    \<0.001   0.79   0.53--1.20    0.271

HR, hazard ratio; CI, confidence interval; WDR54, WD repeat domain 54; RPL26L1, ribosomal protein L26 like 1; PSMC1, proteasome 26S subunit, ATPase 1; SRPX, sushi repeat containing protein, X-linked; SMS, spermine synthase; MTFMT, mitochondrial methionyl-tRNA formyltransferase; CNFN, cornifelin; CLEC10A, C-type lectin domain containing 10A; LRRC38, leucine rich repeat containing 38; RAB24, member RAS oncogene family; PTPN9, protein tyrosine phosphatase, non-receptor type 9; ZNF266, zinc finger protein 266; CIITA, class II major histocompatibility complex transactivator; IL1RAP, interleukin 1 receptor accessory protein.

###### 

Twenty ([@b20-ol-0-0-10213]) random combination performance in datasets.

  Combination/dataset                                                                                                                                                      E302       GSE10300   GSE41613   TCGA-OS
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------- ---------- ---------- ------------
  ENSG00000245213, ENSG00000212694, LRRC38, NEK6, FOXN1, SRPX, CALML5, STC1, DOT1L, SPOCK1, P4HA1, ZNF823, CLEC10A, EXPH5, MAST4, AHSG, CNFN                               0.034280   0.029630   0.040090     0.000003
  ZNF266, STC1, B4GALNT1, PIK3C2B, SSR3, RPL26L1, ENSG00000265206, ENSG00000261269, GPN1, CALML5, TOR1A, AREG, ZBED6CL, SNX20, PPFIBP2, ENSG00000258634, ENSG00000228863   0.047550   0.029340   0.039440   0.001180
  GABARAPL2, ENSG00000258634, MRPS23, EZH1, TOMM34, VEPH1, SH3BP5L, IL2RG, AREG, ZNF266, SPOCK1, SRPX, ALG2, FOXN1, ZNF697, OSGIN2, ENSG00000261408                        0.087940   0.258250   0.943440   0.058420
  ENSG00000261408, ZNF266, PSMC1, RPL26L1, WDR54, ENSG00000265206, IL1RAP, CLEC10A, SMS, SRPX, PTPN9, RAB24, LRRC38, ENSG00000261777, MTFMT, CNFN, CIITA                   0.013950   0.045830   0.000290   0.006270
  RPL26L1, ENSG00000271870, MRPS23, TOR1A, CNFN, NAT8L, IL2RG, LIF, CSTA, LTB, P2RY14, PTPN9, SPINK5, UNK, MAST4, ENSG00000228863, ENSG00000212694                         0.116500   0.026790   0.000390   0.987820
  SSR3, FOXN1, EZH1, SRPX, ZNF266, PLOD2, CLEC10A, LTB, MRPS23, STC1, SPOCK1, BOD1, SGCE, BFAR, SMS, ALG2, CALML5                                                          0.186930   0.239400   0.239550   0.166820
  OSGIN2, STC1, SMS, ENSG00000261269, PIK3C2B, SSR3, CNFN, GABARAPL2, GRIN3A, ARHGAP30, CLEC10A, BFAR, RASSF2, MSANTD3, IL2RG, SYT14, BOD1                                 0.268740   0.807370   0.093000   0.000001
  GAL3ST1, AQP1, ADAP2, MRPS23, ICOS, CAMK2N1, LRRC38, SPINK5, PIK3C2B, CSTA, CIITA, PLOD2, EZH1, PSMC1, ENSG00000261777, ENSG00000212694, GABARAPL2                       0.435250   0.132970   0.000002   0.000017
  ZNF823, CRIPAK, PLOD2, SPOCK1, TRIM32, EZH1, MSANTD3, WDR54, TBC1D17, ENSG00000261269, GPN1, TOR1A, GAL3ST1, CNFN, XPR1, PSMC1, VEPH1                                    0.506950   0.441650   0.000008   0.005540
  HMGA2, IL2RG, TRIM32, WDR54, CALML5, RABEP2, ZNF266, PTPN9, CSTA, LRRC38, CNFN, SH3BP5L, P4HA1, ENSG00000228863, VEPH1, HSD17B7, MAST4                                   0.529010   0.553860   0.045470   0.360270
  TRIM32, MSANTD3, NAT8L, CSTA, ENSG00000261408, SPOCK1, BOD1, CLEC10A, LIF, RPL26L1, CIITA, IL2RG, EZH1, ENSG00000245213, ADAP2, LTB, GPN1                                0.625440   0.928520   0.928520   0.000350
  TRIM32, ENSG00000265206, ENSG00000261040, IL1RAP, RABEP2, SYT14, GAL3ST1, CNFN, ENSG00000258634, WDR54, LIF, SPOCK1, PSMC1, ENSG00000271870, PIK3C2B, ZNF697, ADAP2      0.637600   0.596900   0.600430   0.552850
  CIITA, BFAR, SMS, WDR54, GRIN3A, GPN1, CRIPAK, P2RY14, MTFMT, RASSF2, ENSG00000258634, SPINK5, MSANTD3, HMGA2, DOT1L, ZBED6CL, ZNF697                                    0.643950   0.270340   0.872530   0.322990
  HSD17B7, LIF, EZH1, SMS, PSMC1, WDR54, FOXN1, GABARAPL2, ZNF266, NEK6, SSR3, HMGA2, XPR1, OSGIN2, ALG2, SNX20, AHSG                                                      0.713340   0.078270   0.004130   0.000030
  EXPH5, TBC1D17, P2RY14, DENND2D, PSMC1, AQP1, RABEP2, CAMK2N1, ENSG00000212694, CRIPAK, ENSG00000271870, HMGA2, SPINK5, HSD17B7, ZBED6CL, LTB, ENSG00000265206           0.715320   0.883560   0.130070   0.925960
  ENSG00000261040, VEPH1, IL1RAP, AHSG, TRIM32, DOT1L, MAST4, CAMK2N1, LRRC38, SYT14, P4HA1, TBC1D17, CRIPAK, ZNF697, ENSG00000212694, RAB24, ADAP2                        0.773310   0.214790   0.720550   0.196580
  ADAP2, SPINK5, P4HA1, ALG2, ZNF823, ARHGAP30, XPR1, CALML5, HMGA2, EXPH5, AREG, DOT1L, RABEP2, RASSF2,                                                                   0.784390   0.944440   0.309290   0.874740
  RPL26L1, PPFIBP2, PLOD2, DOT1L, GABARAPL2, LTB, ZNF823, ICOS, SPINK5, PCF11, FOXN1, RASSF2, BOD1, NEK6, SRPX, ENSG00000261408, THBS1                                     0.876380   0.621280   0.000017   0.000650
  LTB, SPOCK1, BOD1, ALG2, CNFN, SRPX, OSGIN2, PCMT1, MTFMT, PSMC1, GPN1, CRIPAK, PIK3C2B, ARHGAP30, AHSG, AQP1, DOT1L                                                     0.936720   0.264460   0.022270   0.333580
  TRIM32, MTFMT, ENSG00000265206, PTPN9, XPR1, NEK6, TOMM34, ZNF266, DENND2D, NAT8L, RAB24, PLOD2, SPOCK1,                                                                 0.963480   0.342870   0.004220   0.000067

HMGA2, ENSG00000245213, AQP1, LIF
